Federal health agencies acknowledge therapeutic potential of psychedelics
The heads of the Food and Drug Administration (FDA) and the National Institutes of Health (NIH) coauthored a new letter describing that status of research into psychedelic drugs such as psilocybin, LSD and ibogaine.
The letter… contains surprising admissions about the therapeutic potential of these federally prohibited controlled substances. It comes in response to an inquiry from Sen. Brian Schatz (D-HI), who requested information about the government’s research agenda on investigating the medical value of psychedelics as well as any plans the agencies have to recommend rescheduling them under the Controlled Substances Act. Psychedelics present an “opportunity to provide treatment to patients while expanding psychotherapy treatment options,” the senator wrote. [In response] the heads of the Food and Drug Administration (FDA) and the National Institutes of Health (NIH)… acknowledged throughout their response that psilocybin, LSD, MDMA, ketamine and ibogaine hold therapeutic promise and can help uncover “mechanisms of illness and possible interventions, ultimately leading to novel treatments with fewer side effects and lower abuse potential … in addition, these findings may hold clues to the roots of psychopathology and consciousness and may accelerate the discovery of new treatments…”
Original Article (Marijuana Moment):
Federal Health Agencies acknowledge therapeutic potential of psychedelics
Artwork Fair Use: icon leak & Sebastien Gabriel
Recent Comments